Prosecution Insights
Prosecution Insights
12 pending office actions • 10 art units • 12 examiners • 0 of 12 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (8%) |
| §103 only | 2 (17%) |
| §102 only | 1 (8%) |
| §112 only | 2 (17%) |
| Double-patenting + other | 1 (8%) |
| Multi-statute (no §101) | 4 (33%) |
| No statute on record | 1 (8%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEADMAN, DAVID J | 1 | 57.7% | +29.5% |
| BARRON, SEAN C | 1 | 53.3% | +30.6% |
| CHICKS, ASHLI ARIANA | 1 | 63.2% | +45.9% |
| MOSELEY II, NELSON B | 1 | 67.8% | +41.6% |
| HALL, DEANNA K | 1 | 75.6% | +15.7% |
| POLIAKOVA-GEORGAN, EKATERINA | 1 | 64.0% | +17.9% |
| VALLE, ERNESTO | 1 | 56.0% | +41.3% |
| HIRAKIS, SOPHIA P | 1 | 52.2% | +73.3% |
| ABUZEINEH, HANAN ISAM | 1 | 56.0% | +51.4% |
| MOORE, SUSANNA | 1 | 67.9% | +31.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18894875 | SMALL NEAR-INFRARED FLUORESCENT PROTEINS DEVELOPED FROM CYANOBACTERIOCHROME AND METHODS FOR THEIR ENGINEERING | STEADMAN, DAVID J | — |
| 18687436 | METHODS FOR THE GENERATION OF HUMAN RETINAL GANGLION CELLS AND COMPOSITIONS, ASSAYS, DEVICES, AND KITS COMPRISING SAME | BARRON, SEAN C | — |
| 18405839 | TMIGD2 AND ITS DERIVATIVES AS BLOCKERS OR BINDERS OF CANCER-EXPRESSED HHLA2 FOR IMMUNOTHERAPIES | MOSELEY II, NELSON B | — |
| 18043441 | COMPOUNDS AND METHODS FOR INHIBITION OF BAX-MEDIATED CELL DEATH | HIRAKIS, SOPHIA P | — |
| 17905325 | A METHOD TO GENERATE CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS (CAR-T CELLS) FROM PATHOGEN-SPECIFIC CYTOTOXIC LYMPHOCYTES TO ENABLE THE SUBSEQUENT IN VIVO MODULATION OF THEIR FUNCTIONAL ACTIVITY | ABUZEINEH, HANAN ISAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18247152 | METHODS OF TREATING VIRAL INFECTIONS WITH PiRNAS OR EXTRACELLULAR VESSICLES RELEASED FROM NEURAL STEM CELLS OR NEURAL PROGENITOR CELLS | POLIAKOVA-GEORGAN, EKATERINA | 14d |
| 18294459 | METHOD OF TREATING AND/OR PREVENTING TYPE 1 DIABETES WITH CEPHARANTHINE | CHICKS, ASHLI ARIANA | 26d |
| 17855772 | COMPOSITIONS AND METHODS FOR PROVIDING CARDIOPROTECTIVE EFFECTS | MOORE, SUSANNA | 28d |
| 18894875 | SMALL NEAR-INFRARED FLUORESCENT PROTEINS DEVELOPED FROM CYANOBACTERIOCHROME AND METHODS FOR THEIR ENGINEERING | STEADMAN, DAVID J | — |
| 18687436 | METHODS FOR THE GENERATION OF HUMAN RETINAL GANGLION CELLS AND COMPOSITIONS, ASSAYS, DEVICES, AND KITS COMPRISING SAME | BARRON, SEAN C | — |
| 18405839 | TMIGD2 AND ITS DERIVATIVES AS BLOCKERS OR BINDERS OF CANCER-EXPRESSED HHLA2 FOR IMMUNOTHERAPIES | MOSELEY II, NELSON B | — |
| 18487659 | NITRIC OXIDE-RELEASING DEVICE | HALL, DEANNA K | — |
| 18044606 | COMBINATION THERAPY USING BAX ACTIVATOR AGENT | VALLE, ERNESTO | — |
| Art Unit | Apps |
|---|---|
| 1623 | 2 |
| 1653 | 1 |
| 1626 | 1 |
| 1642 | 1 |
| 3783 | 1 |
| 1637 | 1 |
| 1633 | 1 |
| 1624 | 1 |
| 1634 | 1 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18894875 | SMALL NEAR-INFRARED FLUORESCENT PROTEINS DEVELOPED FROM CYANOBACTERIOCHROME AND METHODS FOR THEIR ENGINEERING | STEADMAN, DAVID J | — | §102§112 | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18687436 | METHODS FOR THE GENERATION OF HUMAN RETINAL GANGLION CELLS AND COMPOSITIONS, ASSAYS, DEVICES, AND KITS COMPRISING SAME | BARRON, SEAN C | 1653 | §103§112 | Non-Final OA | — | Pending | Feb 28, 2024 |
| 18294459 | METHOD OF TREATING AND/OR PREVENTING TYPE 1 DIABETES WITH CEPHARANTHINE | CHICKS, ASHLI ARIANA | 1626 | §103Other | Non-Final OA | 26d | Pending | Feb 01, 2024 |
| 18405839 | TMIGD2 AND ITS DERIVATIVES AS BLOCKERS OR BINDERS OF CANCER-EXPRESSED HHLA2 FOR IMMUNOTHERAPIES | MOSELEY II, NELSON B | 1642 | §101§103Other | Non-Final OA | — | Pending | Jan 05, 2024 |
| 18487659 | NITRIC OXIDE-RELEASING DEVICE | HALL, DEANNA K | 3783 | §102 | Non-Final OA | — | Pending | Oct 16, 2023 |
| 18247152 | METHODS OF TREATING VIRAL INFECTIONS WITH PiRNAS OR EXTRACELLULAR VESSICLES RELEASED FROM NEURAL STEM CELLS OR NEURAL PROGENITOR CELLS | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §112 | Final Rejection | 14d | Pending | Mar 29, 2023 |
| 18044606 | COMBINATION THERAPY USING BAX ACTIVATOR AGENT | VALLE, ERNESTO | 1623 | §102§103§112DP | Non-Final OA | — | Pending | Mar 09, 2023 |
| 18043441 | COMPOUNDS AND METHODS FOR INHIBITION OF BAX-MEDIATED CELL DEATH | HIRAKIS, SOPHIA P | 1623 | §102§103§112 | Final Rejection | — | Pending | Feb 28, 2023 |
| 17905325 | A METHOD TO GENERATE CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS (CAR-T CELLS) FROM PATHOGEN-SPECIFIC CYTOTOXIC LYMPHOCYTES TO ENABLE THE SUBSEQUENT IN VIVO MODULATION OF THEIR FUNCTIONAL ACTIVITY | ABUZEINEH, HANAN ISAM | 1633 | §102§103 | Final Rejection | — | Pending | Aug 30, 2022 |
| 17855772 | COMPOSITIONS AND METHODS FOR PROVIDING CARDIOPROTECTIVE EFFECTS | MOORE, SUSANNA | 1624 | §112Other | Final Rejection | 28d | Pending | Jun 30, 2022 |
| 17278439 | INTERLEUKIN-8 FOR MAINTENANCE OF HUMAN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME AND USES THEREOF | PENNINGTON, KATIE LEIGH | 1634 | §103 | Non-Final OA | — | Pending | Mar 22, 2021 |
| 17527488 | TREATMENT OF CANCER USING RECALL ANTIGENS DELIVERED BY ATTENUATED BACTERIA | FORD, VANESSA L | 1645 | — | Non-Final OA | — | Pending | Nov 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial